Purchase Order 75D30124P20000

Award Date 8/30/24
Potential Completion Date 9/30/24
Potential Value $142K
Federal Agency
CDC Pittsburgh
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Marshallton, DE 19808, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $95,700 firm fixed-price purchase order contract awarded by the Centers for Disease Control and Prevention (CDC) to Biolytic Lab Performance Inc., a veteran-owned for-profit company specializing in DNA synthesis solutions and laboratory equipment. The contract is for the procurement of a DR.OLIGO 48 DNA synthesizer, which allows the CDC to synthesize oligonucleotides at a much higher capacity with reduced turnaround time and argon gas consumption. This sole-source contract is based...
This is a $16,438.00 firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Integrated DNA Technologies, Inc. (IDT) for the delivery of custom laboratory oligonucleotides. The contract has no set-aside designation. IDT is a leading manufacturer and supplier of specialized nucleic acid products and services to federal agencies, supporting initiatives such as biomedical research, pandemic response, and public health programs. This award is part of...
This is a firm fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Biolytic Lab Performance Inc., a veteran-owned for-profit organization. The contract, valued at $84,950.00, is for the provision of an OLIGO INST (oligonucleotide instrument), with a performance period ending on July 20, 2021. The contract has no set-aside designation. Biolytic Lab Performance Inc. is a provider of DNA synthesis solutions and laboratory equipment, having secured...
The Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh awarded a $119,358.58 firm-fixed-price purchase order to Agilent Technologies, Inc. for the purchase of OLIGO PRO II scientific equipment. The contract does not have a set-aside designation. Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets, providing analytical instruments, software, and services to federal agencies including the Department of...
This is a firm-fixed-price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Eurofins Genomics LLC, a for-profit manufacturer of goods, to produce oligonucleotides for the CDC's Rapid Production of Oligonucleotides for Circulating Vaccine-Derived Poliovirus (OLIGO CVV RAPID PRODUCTION) program. The contract has a ceiling value of $171,193.00 and a period of performance ending on September 25, 2025. The contract does not have a set-aside designation. Eurofins...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Agilent Technologies Inc., a manufacturer of scientific instruments and equipment. The contract is for customized reagent kits required for human papillomavirus (HPV) whole genome sequencing using Agilent's SureSelect target enrichment technology and bioinformatics support. The contract has a ceiling value of $89,678.52 and an ultimate completion date of October 27, 2018. The order was...
The Centers for Disease Control and Prevention (CDC) awarded a $95,931 firm-fixed-price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a MiSeq next-generation DNA sequencing system. This sole-source award is intended to support the CDC's public health need for enhanced monitoring of HIV drug resistance in countries receiving PEPFAR (President's Emergency Plan for AIDS Relief) funding. Illumina was selected as the sole source due to its...
This firm-fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Integrated DNA Technologies, Inc. (IDT) for the provision of SPIKE PRIMER SETS AND AMPLICON PANEL, with a ceiling value of $187,940.00 and a period of performance ending on September 29, 2024. The award was made on a sole-source basis, as IDT is the only manufacturer of the proprietary "XGEN" technology validated by the CDC for whole genome sequencing of SARS-CoV-2 to support...
This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Life Technologies Corporation, a manufacturer of scientific instruments, reagents, and consumables. The contract is for the annual maintenance and inspection of the CDC's existing ION CHEF SVC and ION S5 PLUS SEQUENCER instruments located in Atlanta, Georgia. The award, valued at $121,259.80, has a performance period ending on May 18, 2028. As this is a sole source contract for...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a firm fixed-price purchase order contract to Biolytic Lab Performance Inc., a veteran-owned for-profit organization, for the procurement of a DR. OLIGO Synthesizer. The contract, valued at $84,950.00, has an ultimate completion date of April 30, 2020. Biolytic Lab Performance Inc. is a federal contractor that specializes in DNA synthesis solutions and laboratory equipment, and has secured multiple awards from various civilian and...

This is a sole source purchase order awarded by the Centers for Disease Control and Prevention (CDC) to Agilent Technologies Inc. for the procurement of Oligo Pro II supplies or services. The contract action is being pursued under the authority of FAR 13.106-1(b) and 41 U.S.C. 3304(a)(1), which allows for sole source procurement without competition. The key requirements include fast separations, wide sizing range, single base resolution through 60-mers, variable throughput, and direct detection of oligonucleotides without dye labeling. The CDC has justified the sole source determination based on the Oligo Pro II system's unique capabilities and the existing use of older models within the agency. This contract has a ceiling value of $142,438.19 and an ultimate completion date of September 30, 2024. The contract is not set aside for any specific business category.

Generated 12/13/24, 9:10 AM